GC
BHVN

Guggenheim Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Guggenheim Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,291
Closed -$3.22M – 2051
2022
Q3 		$3.22M Sell
21,291
-5,754
-21% -$853K 0.03% 664
2022
Q2 		$3.94M Buy
27,045
+2,826
+12% +$361K 0.03% 643
2022
Q1 		$2.87M Sell
24,219
-179
-0.7% -$22.3K 0.02% 869
2021
Q4 		$3.36M Buy
24,398
+5,477
+29% +$696K 0.02% 837
2021
Q3 		$2.63M Sell
18,921
-5,131
-21% -$641K 0.02% 916
2021
Q2 		$2.33M Sell
24,052
-4,043
-14% -$328K 0.01% 1011
2021
Q1 		$1.92M Buy
28,095
+2,312
+9% +$187K 0.01% 1057
2020
Q4 		$2.21M Buy
+25,783
New +$2.18M 0.01% 928

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Guggenheim Capital's BHVN Position: Q4 2022 in Review

Guggenheim Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 21,291 shares — an estimated $3.22M sold.

Guggenheim Capital first reported a position in BHVN in Q4 2020 and held it in 8 quarters. The position peaked at $3.94M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Guggenheim Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Guggenheim Capital sold 21,291 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $3.22M.
  • Guggenheim Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 8 quarters.
  • Guggenheim Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.94M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Guggenheim Capital's 13F filing for Q4 2022, filed 14 Feb 2023.